Literature DB >> 20534818

Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers.

Jeanne Mendell1, Masaya Tachibana, Minggao Shi, Satoshi Kunitada.   

Abstract

The primary objective of this study was to assess the effect of a standard high-fat meal on the single-dose (60 mg) pharmacokinetics (PK) of edoxaban in healthy Japanese and Caucasian male volunteers matched by body mass index. This was an open-label, randomized, 2-period crossover study. All 32 enrolled volunteers completed the study per protocol. Both serial blood and urine samples were collected, and edoxaban concentrations were analyzed by a validated liquid chromatography/tandem mass spectrometry method. Activated partial thromboplastin and prothrombin times were obtained as measures of pharmacodynamic effect. The point estimates of the geometric mean ratios (fed/fasted) for AUC(0-t), AUC(0-∞), and C(max) demonstrated modest increases ranging from 6% to 22% across PK parameters for both race cohorts. The disposition was similar in both Japanese and Caucasian matched volunteers with slightly higher AUC values (ranging from 7%-9%) in Caucasians. There were no serious adverse events during the study. All drug-related adverse events were mild and self-limited, and none were bleeding related. Both Japanese and Caucasian volunteers demonstrated a modest but clinically insignificant food effect. It was concluded that edoxaban can be administered without regard to food.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20534818     DOI: 10.1177/0091270010370974

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  30 in total

1.  Edoxaban.

Authors:  Dennis J Cada; Danial E Baker; Kyle Ingram
Journal:  Hosp Pharm       Date:  2015-07-31

Review 2.  Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review.

Authors:  Adam Cuker; Holleh Husseinzadeh
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

Review 3.  The pharmacology of novel oral anticoagulants.

Authors:  Tracy A DeWald; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

Review 4.  Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.

Authors:  Bethany T Samuelson; Adam Cuker; Deborah M Siegal; Mark Crowther; David A Garcia
Journal:  Chest       Date:  2016-09-13       Impact factor: 9.410

Review 5.  Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance.

Authors:  Karlyn A Martin; Craig R Lee; Timothy M Farrell; Stephan Moll
Journal:  Am J Med       Date:  2017-02-01       Impact factor: 4.965

Review 6.  Pharmacology of the new target-specific oral anticoagulants.

Authors:  Katherine P Cabral
Journal:  J Thromb Thrombolysis       Date:  2013-08       Impact factor: 2.300

7.  Direct oral anticoagulants (DOACs) and neck of femur fractures: Standardising the perioperative management and time to surgery.

Authors:  Rohi Shah; Nomaan Sheikh; Jitendra Mangwani; Nicolette Morgan; Hamidreza Khairandish
Journal:  J Clin Orthop Trauma       Date:  2020-08-23

Review 8.  Oral anticoagulants for Asian patients with atrial fibrillation.

Authors:  Ian Sabir; Kaivan Khavandi; Jack Brownrigg; A John Camm
Journal:  Nat Rev Cardiol       Date:  2014-03-11       Impact factor: 32.419

Review 9.  Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice.

Authors:  Alberto Corsini; Nicola Ferri; Marco Proietti; Giuseppe Boriani
Journal:  Drugs       Date:  2020-07       Impact factor: 9.546

Review 10.  Novel oral anticoagulants: clinical pharmacology, indications and practical considerations.

Authors:  Sebastian Harder; Jochen Graff
Journal:  Eur J Clin Pharmacol       Date:  2013-04-26       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.